期刊文献+

IHC法与FISH法检测乳腺癌HER-2基因结果比较 被引量:4

Comparison of IHC method and FISH method in detection of breast cancer HER-2 gene
在线阅读 下载PDF
导出
摘要 目的比较免疫组织化学法(IHC)法和荧光原位杂交(FISH)法检测女性乳腺癌HER-2基因结果的可靠性。方法采用FISH双色法检测原发性浸润性乳腺癌中的HER-2基因及IHC检测HER-2蛋白表达情况,两者进行对比分析。结果在259例乳腺癌患者中,FISH检测阳性125例,IHC检测阳性239例,2者比较有显著性差异。将FISH结果和IHC结果进行分组比较,IHC为()者,FISH阳性率为76.19%;IHC为()者,FISH阳性率为52.25%。表明FISH和IHC有显著相关性。17号染色体非整倍体是造成IHC过度表达但FISH检测为阴性的主要原因。结论 IHC检测受实验室因素和主观因素影响,17号染色体非整倍体也是造成IHC过表达但基因不扩增的主要原因,所以确定HER-2扩增情况用FISH法检测更准确,能对患者的预后情况和治疗方案的选择提供更科学的依据。 Objective It is to compare the reliability of results in exploration of female breast cancer HER - 2 gene by im- munohistochemical (IHC) method and fluorescence in situ hybridization (FISH) method. Methods The expression of HER - 2 gene in primary invasive breast carcinoma was detected by FISH two-color assay, and the expression of HER - 2 protein was detected by IHC method, then the results was compared and analyzed. Results In 259 patients with breast cancer, there were 125 cases with FISH of positive, 239 cases with IHC of positive; there was significant difference between them. By group com- parison, the FISH positive rate was 76.19% while IHC for (3 + ) , and the FISH positive rate was 52.25% while IHC for (2 + ). There was significant positive correlation between FISH and IHC. The 17 chromosome aneuploidy was the main cause of IHC excessive expression but FISH detection for negative. Conclusion IHC detection is influenced by the factors of laboratory and subjective effects. The aneuploidy of chromosome 17 is the main cause of excessive expression of IHC but gene doesn' t amplification. So the identification of HER - 2 amplification by FISH assay is more accurate, the patient prognosis and treat- ment options to provide more scientific basis.
作者 张喆 徐玮
机构地区 江苏省肿瘤医院
出处 《现代中西医结合杂志》 CAS 2013年第12期1267-1269,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 乳腺癌 HER-2 基因 荧光 原位杂交 免疫组织化学 17号染色体 breast cancer HER- 2 gene fluorescence in situ hybridization immunohistochemistry chromosome 17
  • 相关文献

参考文献10

  • 1Kasof GM, Comes BC,Livin, a novel inhibitor of apoptosis protein family member[ J]. J Biol Chem ,2001,276 (2) :3238 - 3246.
  • 2Shin SJ,Hyjek E,Early E,et al. Int ratumoral heterogeneity of her22/ neu in invasive mammary carcinomasusing fluoreseence in situ hybridization and tissue microarray[ J]. lnt J Surg Pathol,2006,14 : 279 - 284.
  • 3Egervari K, Szollosi Z, Nemes Z. Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study[ J]. Tumour Biol, 2008,29(1) :18 -27.
  • 4俞巍,谷俊朝,徐秀红,宋茂民,白庆阳,刘建中.荧光原位杂交法检测乳腺癌HER-2/neu表达及临床意义[J].首都医科大学学报,2009,30(1):93-96. 被引量:7
  • 5Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials [ J]. Clin Cancer Res,2005,11:6598 - 6607.
  • 6Ross JS,Fletcher JA. The HER- 2/neu oncogene: Prognostic factor, predictive factor and target for therapy[ J ]. Semin Cancer Biol, 1999,9:125 - 138.
  • 7Slamon DJ,Godolphin W,Jones LA,et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer [ J ]. Science, 1989,244 : 707 - 712.
  • 8Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of erbB2 in human breast cancer: impact of fixation [ J ]. J Pathol, 1994,173:65 - 75.
  • 9王晓兰,姚凡,刘楠,吴云,郑新宇,李继光,邱雪杉,金锋.FISH在乳腺癌组织HER2/neu原癌基因检测上的应用及其临床意义的研究[J].中国医科大学学报,2008,37(5):664-666. 被引量:17
  • 10Hammock L,Lewis M, Phillips C, et al. Strong HER -2/neu protein overexpression by immunohistochemistry of ten does not predictoncogene am plification by fluorescence in situ hybridization [ J]. Htim Pathol ,2003,34 : 1043 - 1047.

二级参考文献20

  • 1焦德,任国胜.HER 2基因在乳腺癌中的研究进展[J].国外医学(外科学分册),2005,32(5):374-378. 被引量:3
  • 2谢永红,林雪平,李继承.绝经前和绝经后乳腺癌患者中ER、nm23-H1、c-erbB-2基因的表达及其关系[J].实用肿瘤杂志,2007,22(2):150-152. 被引量:2
  • 3WU F, HU CH,JIANG SA, et al. Herceptin plus adjuvant chemotherapy for the prognosis of patients with human epithelial growth factor receptor 2 positive early-stage breast cancer:a meta-analysis [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2007,32(4) : 684-689.
  • 4KIMURA M,SANO M,FUJIMORI M,et al. Neoadjuvant paclitaxel for operable breast cancer:multicenter phase Ⅱ trial with clinical outcomes[J]. Anticancer Res, 2008,28 (2B) : 1239-1244.
  • 5CHEN SC,CHANG HK,LIN YC,et al. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin [J ]. Jpn J Clin Oncol,2008,38(2):99-105.
  • 6PETIT T, BOREL C, GHNASSIA JP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting [J]. Clin Cancer Res,2001,7 (6): 1577-1551.
  • 7GAGO FE, FANELLI MA, CIOCCA DR. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer:clinical outcome following tamoxifen-based adjuvant therapy [J]. Steroid Biochem Mol Biol, 2006,98 ( 1 ) : 36-40.
  • 8EGERVARI K, SZOLLOSI Z, NEMES Z. Immunohistochemical anti- bodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study [J]. Tumour Biol, 2008,29( 1 ) : 18-27.
  • 9ROBERT N,LEYLAND-JONES B,ASMAR L,et al. Randomized phase Ⅲ study of transtuzumab,paclitaxel, and carboplatin compared with transtuzumab and paclitaxel in women with HER2-overexpression metastatic breast cancer [J ]. Clin Oncol,2006,24( 18): 2786-2792.
  • 10SMITH I,PROCTER M,GELBER RD,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer: a randomized controlled trial [ J ]. Lancet, 2007,369 (9555) : 29-36.

共引文献21

同被引文献30

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部